Guggenheim lowered the firm’s price target on R1 RCM to $15 from $17 and keeps a Buy rating on the shares. The reduced target reflects risk that RCM goes private at a price lower than the previous target and the disruption associated with delayed reimbursements caused by the Change Health cyberattack, the analyst tells investors in a research note. However, the firm thinks the company is set to grow EBITDA in the mid-teens in 2025 and 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCM:
- R1 RCM to Release First Quarter 2024 Results on May 8, 2024
- R1 Releases Fourth Annual Environmental, Social and Governance (ESG) Report
- R1 RCM price target lowered to $16 from $17 at Canaccord
- R1 RCM upgraded to Buy from Neutral at Citi
- LifeStance named Top Pick in Healthcare Technology at Morgan Stanley
